TY - JOUR
T1 - Deep brain stimulation for treatment-resistant depression
AU - Schläpfer, T. E.
AU - Kayser, S.
N1 - Funding Information:
This study was supported by a distinguished Investigator Award to H.S.M. from the National Alliance for Research in Schizophrenia and Depression (NARSAD). We thank Kari Fulton for patient screening and coordination; Doug Hussey and Alvina Ng for acquisition of the PET studies; Jonathan Dostrovsky and William Hutchison for intraoperative electrophysiological studies; Jean Saint-Cyr for assistance with MR imaging; and Stanley Mayberg and Paul Holzheimer for critical review of the manuscript.
PY - 2014/6
Y1 - 2014/6
N2 - About 30% of depressed patients still suffer from considerable residual symptoms despite treatment with established therapies such as antidepressants and psychotherapy. These treatment-resistant depressed (TRD) patients often have severe limitations in their quality of life. New brain stimulation techniques such as deep brain stimulation (DBS) in TRD show in different targets in the brain consistently a positive antidepressant efficacy. Nowadays, the most researched targets of DBS for TRD patients are the internal capsule interna, the subgenuale cingulate cortex (Brodman area, Cg25), the nucleus accumbens and the supero-lateral area of the medial forebrain bundle (supero-lateral branch of the medial forebrain bundle, slMFB). Anhedonia as a core symptom of depression is believed to be most affected by the stimulation of the nucleus accumbens and the slMFB. The fastest and most significant antidepressant effects are shown by the stimulation in the slMFB with a response rate of 85% within a few days.
AB - About 30% of depressed patients still suffer from considerable residual symptoms despite treatment with established therapies such as antidepressants and psychotherapy. These treatment-resistant depressed (TRD) patients often have severe limitations in their quality of life. New brain stimulation techniques such as deep brain stimulation (DBS) in TRD show in different targets in the brain consistently a positive antidepressant efficacy. Nowadays, the most researched targets of DBS for TRD patients are the internal capsule interna, the subgenuale cingulate cortex (Brodman area, Cg25), the nucleus accumbens and the supero-lateral area of the medial forebrain bundle (supero-lateral branch of the medial forebrain bundle, slMFB). Anhedonia as a core symptom of depression is believed to be most affected by the stimulation of the nucleus accumbens and the slMFB. The fastest and most significant antidepressant effects are shown by the stimulation in the slMFB with a response rate of 85% within a few days.
KW - anhedonia
KW - antidepressive effect
KW - capsule interna
KW - deep brain stimulation
KW - nucleus accumbens
KW - subgenuale cingulate cortex
KW - supero-lateral branch of the medial forebrain bundle
KW - therapy-resistant depression
UR - http://www.scopus.com/inward/record.url?scp=84903777571&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84903777571&partnerID=8YFLogxK
U2 - 10.1055/s-0034-1375605
DO - 10.1055/s-0034-1375605
M3 - Article
AN - SCOPUS:84903777571
SN - 1434-0275
VL - 45
SP - 113
EP - 117
JO - Klinische Neurophysiologie
JF - Klinische Neurophysiologie
IS - 2
ER -